Evidence map›Paper›PMID 29753029›Full record

ArticleThe Journal of investigative dermatology2018

Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes.

Nancy E Thomas, Sharon N Edmiston, Irene Orlow, Peter A Kanetsky, Li Luo, David C Gibbs, Eloise A Parrish, Honglin Hao, Klaus J Busam, Bruce K Armstrong and 14 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of investigative dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma.Virchows Archiv : an international journal of pathology · 2024
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 13 institutions in 5 countries.

Nancy E ThomasDepartment of Dermatology, University of North Carolina, Chapel Hill, North Carolina, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA. Electronic address: nthomas@med.unc.edu.
Sharon N EdmistonDepartment of Dermatology, University of North Carolina, Chapel Hill, North Carolina, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Irene OrlowDepartment of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA.
Peter A KanetskyDepartment of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Li LuoDepartment of Internal Medicine, University of New Mexico Cancer Center, University of New Mexico, Albuquerque, New Mexico, USA.
David C GibbsDepartment of Epidemiology, Emory University, Atlanta, Georgia, USA.
Eloise A ParrishDepartment of Dermatology, University of North Carolina, Chapel Hill, North Carolina, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Honglin HaoDepartment of Dermatology, University of North Carolina, Chapel Hill, North Carolina, USA.
Klaus J BusamDepartment of Pathology, Memorial Sloan-Kettering Cancer Center, New York, USA.
Bruce K ArmstrongSchool of Public and Global Health, The University of Western Australia, Perth, Australia.
Anne KrickerSydney School of Public Health, The University of Sydney, Sydney, Australia.
Anne E CustSydney School of Public Health, The University of Sydney, Sydney, Australia; Melanoma Institute Australia, The University of Sydney, North Sydney, Australia.
Hoda Anton-CulverDepartment of Epidemiology, University of California, Irvine, California, USA.
Stephen B GruberUSC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, USA.
Richard P GallagherBritish Columbia Cancer and Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada.
Roberto ZanettiPiedmont Cancer Registry, Centre for Epidemiology and Prevention in Oncology in Piedmont, Turin, Italy.
Stefano RossoPiedmont Cancer Registry, Centre for Epidemiology and Prevention in Oncology in Piedmont, Turin, Italy.
Lidia SacchettoPiedmont Cancer Registry, Centre for Epidemiology and Prevention in Oncology in Piedmont, Turin, Italy; Politecnico di Torino, Turin, Italy.
Terence DwyerGeorge Institute for Global Health, Nuffield Department of Obstetrics and Gynecology, University of Oxford, Oxford, UK.
David W OllilaLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA; Department of Surgery, University of North Carolina, Chapel Hill, North Carolina, USA.
Colin B BeggDepartment of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA.
Marianne BerwickDepartment of Internal Medicine, University of New Mexico Cancer Center, University of New Mexico, Albuquerque, New Mexico, USA.
Kathleen ConwayDepartment of Dermatology, University of North Carolina, Chapel Hill, North Carolina, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA; Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA.
GEM Study Group
University of North Carolina at Chapel Hill · USMemorial Sloan Kettering Cancer Center · USUniversity of New Mexico · USPiedmont Reference Center for Epidemiology and Cancer Prevention · ITThe University of Sydney · AUEmory University · USMoffitt Cancer Center · USThe George Institute for Global Health · GBThe University of Western Australia · AUUniversity of British Columbia · CAUniversity of California, Irvine · USUniversity of Southern California · USPolitecnico di Torino · IT

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa A. Troester · 2001 to 2026
$36.3M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008169 · NIGMS · EMORY UNIVERSITY · PI GROSS, ROBERT E · 1987 to 2021
$20.3M
Sex Differences in Methylome Alterations and Mutational Burden in Early Stage MelanomaP01CA206980 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI BERWICK, MARIANNE, THOMAS, NANCY E. · 2017 to 2022
$10.1M
Melanoma RAS/BRAF Mutation:Heterogeneity-Risk-PrognosisR01CA112243 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI THOMAS, NANCY E. · 2005 to 2014
$5.4M
A MODEL FOR GENETIC SUSCEPTIBILITY: MELANOMAU01CA083180 · NCI · UNIVERSITY OF NEW MEXICO · PI BERWICK, MARIANNE · 1999 to 2003
$5.2M
Solar Exposure and Melanoma SurvivalR01CA112524 · NCI · UNIVERSITY OF NEW MEXICO · PI BERWICK, MARIANNE · 2005 to 2009
$2.5M
Epidemiologic Parameters of Rare Cancer Risk FactorsR01CA098438 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI BEGG, COLIN B · 2003 to 2005
$839k
Melanoma NRAS/BRAF Mutations: A Population-Based StudyK07CA102096 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI THOMAS, NANCY E · 2003 to 2007
$650k
Validation of the use of whole-genome amplified DNA in a population-based studyR03CA173806 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ORLOW, IRENE · 2013 to 2014
$170k
NCI NIH HHS K07 CA102096NCI NIH HHS P01 CA206980NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA016086NCI NIH HHS R01 CA098438NCI NIH HHS R01 CA112243NCI NIH HHS R01 CA112524NCI NIH HHS R03 CA125829NCI NIH HHS R03 CA173806NCI NIH HHS U01 CA083180NIEHS NIH HHS P30 ES010126NIGMS NIH HHS T32 GM008169
6 · The paper itself

Abstract

BRAF and NRAS mutations arise early in melanoma development, but their associations with low-penetrance melanoma susceptibility loci remain unknown. In the Genes, Environment and Melanoma Study, 1,223 European-origin participants had their incident invasive primary melanomas screened for BRAF/NRAS mutations and germline DNA genotyped for 47 single-nucleotide polymorphisms identified as low-penetrant melanoma-risk variants. We used multinomial logistic regression to simultaneously examine each single-nucleotide polymorphism's relationship to BRAF V600E, BRAF V600K, BRAF other, and NRAS+ relative to BRAF-/NRAS- melanoma adjusted for study features. IRF4 rs12203592*T was associated with BRAF V600E (odds ratio [OR] = 0.59, 95% confidence interval [CI] = 0.43-0.79) and V600K (OR = 0.65, 95% CI = 0.41-1.03), but not BRAF other or NRAS+ melanoma. A global test of etiologic heterogeneity (P

Indexed as

GenotypeAdultAgedFemaleGenetic Association StudiesGroup VI Phospholipases A2GTP PhosphohydrolasesHumansInterferon Regulatory Factor-4Interferon Regulatory FactorsMaleMelanomaMembrane ProteinsMiddle AgedMutationPolymorphism, Single NucleotideBRAF protein, humanGroup VI Phospholipases A2GTP PhosphohydrolasesInterferon Regulatory Factor-4Interferon Regulatory FactorsMembrane ProteinsNRAS protein, humanPLA2G6 protein, humanProto-Oncogene Proteins B-raf

Identifiers

PMID29753029
PMCPMC6200630
OpenAlexW2802693169

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.